CG Oncology named Jim DeTore as chief financial officer effective April 13, 2026. DeTore joins the company after serving as interim principal financial and accounting officer since November 2025 and previously holding CFO roles at Neurogastrx, Bluebird Bio and Proteostasis Therapeutics. His background includes leading financial strategy and capital‑market transactions for mid‑sized biopharmaceutical firms.
DeTore’s compensation package includes a base salary of $520,000, an annual target bonus of 45% of salary, and equity awards totaling $5 million in stock options and performance‑based stock units. The performance units are tied to the commercial launch of CG Oncology’s lead product and to achieving consecutive quarters of positive operating cash flow, with a grant date of April 15, 2026.
CG Oncology remains unprofitable, reporting a loss per share of $2.08 for the most recent twelve‑month period. The company’s cash balance stood at $903.0 million as of February 26, 2026, providing a runway through the first half of 2029. The firm’s flagship candidate, cretostimogene grenadenorepvec, has received FDA Fast Track and Breakthrough Therapy designations and is advancing through late‑stage trials for non‑muscle invasive bladder cancer.
The appointment is part of a broader strategy to strengthen financial leadership in anticipation of regulatory milestones and a potential commercial launch of cretostimogene. DeTore’s experience in biopharma finance is expected to support the company’s capital‑raising efforts, manage the financial risks associated with late‑stage development, and prepare the organization for the commercial phase.
Investors have responded positively to the appointment, viewing DeTore’s track record and the company’s robust pipeline as indicators of a solid foundation for future growth. The CFO’s role is seen as a critical component in navigating the upcoming regulatory and commercial milestones for cretostimogene.
The appointment underscores CG Oncology’s commitment to building a leadership team capable of managing the financial complexities of advancing a breakthrough therapy from clinical development to market launch.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.